


Determinazione del Responsabile Ufficio Formazione n° 850 del 28 APR. 2017

Oggetto: Aggiornamento obbligatorio, Dirigente Medico, Dott. Giulio Binaghi.

Publicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 28 APR. 2017 per 15 giorni consecutivi e posta a disposizione per la consultazione.

Il Responsabile dell'Ufficio Formazione

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 51 del 20.04.2017, con la quale il Direttore Dipartimento Patologia Cardiaca ha fatto richiesta di comando obbligatorio per aggiornamento, in favore del Dirigente Medico Dott. Giulio Binaghi;
- Ritenuto** di dover autorizzare la partecipazione del Dott. Giulio Binaghi al Congresso "Heart Failure 2017" che si terrà a Parigi dal giorno 29.04.2017 al giorno 02.05.2017, per un importo presunto di € 1520,00 (millecinquecentoventi euro) come da documentazione allegata per farne parte integrale e sostanziale;
- Considerato** che tale spesa ricadrà sul Fondo per l'aggiornamento obbligatorio Dirigenti Medici - Dipartimento Patologia Cardiaca - anno 2017 di cui risulta verificata la copertura finanziaria e che la liquidazione dei costi sostenuti dovrà essere effettuata previa trasmissione a cura del Dott. Giulio Binaghi della documentazione giustificativa ai competenti Uffici con la relazione sull'aggiornamento e dell'Attestato di partecipazione al Congresso;

%



Segue determinazione n. 850 del 28 APR. 2017

DETERMINA

Per i motivi esposti in premessa:

1. Autorizzare la partecipazione del Dott. Giulio Binaghi al Congresso "Heart Failure 2017" che si terrà a Parigi dal giorno 29.04.2017 al giorno 02.05.2017.
2. Dare atto che l'importo complessivo presunto di € 1520,00 (millecinquecentoventi euro) ricadrà sul Fondo per l'aggiornamento obbligatorio Dirigenti Medici -- Dipartimento Patologia Cardiaca - anno 2017 di cui risulta verificata la copertura finanziaria.
3. Disporre che la liquidazione dei costi sostenuti dal Dott. Giulio Binaghi venga effettuata previa trasmissione ai competenti Uffici della documentazione giustificativa, di una relazione sull'aggiornamento e dell'Attestato di partecipazione al Congresso.
4. Trasmettere la presente determinazione al Direttore della S.C. del Personale per i conseguenti adempimenti.

Il Responsabile dell'Ufficio Formazione
Dott. Andrea Corrias





REGIONE AUTONOMA DELLA SARDEGNA

Azienda Ospedaliera Brotzu

Prot.n. 51 del 20/04/2017

Al Sig. Direttore Generale
Al Responsabile Ufficio Formazione
Azienda Ospedaliera Brotzu
-SEDE-

Oggetto: **Richiesta aggiornamento Obbligatorio**

Si chiede che venga concesso alla/al Sig.ra/Sig. e/o alla/al Dott.ssa/Dott. GIULIO BINAGHI
dipendente di codesta Azienda con la qualifica di DRIGONTS NSMC
in servizio presso: Struttura COMPLESSA DI CARDIOLOGIA
afferrente al Dipartimento di _____

di partecipare

a titolo di aggiornamento **Obbligatorio** e in considerazione dell'importanza degli argomenti trattati, al seguente evento:

- Corso teorico
- Corso teorico/pratico
- Congresso
- Convegno
- Seminario
- Frequenza in altre Strutture
- Altro

Titolo dell'evento: ESC HEART FAILURE 2017

Che si terrà a PERIGI dal giorno 22/4/17 al giorno 02/05/2017

La spesa prevista:

- Iscrizione € 670 €
- Viaggio € 300 €
- Vitto € 200 €
- Pernottamento € 350 €

rimborso analitico

Spesa totale complessiva € 1520 €

Motivazione scientifica e professionale della richiesta:

AGGIORNAMENTO ISMATICHE AFFERONCE NSL
QUOTIDIANO

Cordiali saluti

Si allega: Programma Relazione

Timbro e firma _____
Direttore di Struttura

Timbro e firma _____
Direttore di Dipartimento Dott. Maurizio Sorcu

Timbro e firma _____
Responsabile Ufficio Formazione
UFFICIO FORMAZIONE
Resp.: **Dott. Andrea Corrias**

Sessions by Day













SATURDAY 29 APRIL 2017

<ul style="list-style-type: none"> • Late Breaking Trials I • Organ dysfunction in acute heart failure • Differential diagnosis of dilated cardiomyopathy • Insuffisance cardiaque systolique en consultation • Rapid Fire I - Basic Science 	08:30 - 10:00	MONET ZOLA RENOIR MATISSE AGORA 2
<ul style="list-style-type: none"> • Guidelines in Daily Practice I: atrial fibrillation in heart failure • Getting the patient ready for discharge • Remote monitoring for heart failure • Surveillance post hospitalisation • Understanding cardiomyopathies. What are the mechanisms? • Off the record with L. Warner Stevenson • Rapid Fire 2 - Comorbidities 	11:00 - 12:00	MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Advancing acute heart failure treatment - quo vadis? - Sponsored by Novartis • Furosemide 2.0 - Subcutaneous administration of a novel formulation - Sponsored by scPharmaceuticals, Inc. • Heart failure with reduced ejection fraction and narrow QRS: how baroreflex stimulation help? - Sponsored by Charité Universitätsmedizin Berlin • Treating Functional Mitral Regurgitation (FMR) in heart failure with Transcatheter Mitral Valve Repair (TMVR): rendez-vous with the future now! - Sponsored by ABBOTT STRUCTURAL HEART • Updates on risk guided stratification for primary prevention of sudden cardiac death in heart failure - Sponsored by GE Healthcare 	12:15 - 13:15	HUGO ZOLA RENOIR MATISSE PIAF
<ul style="list-style-type: none"> • Journey of a heart failure patient: similarities and differences across the world - Sponsored by SERVIER • Novel transcatheter options for functional mitral regurgitation in heart failure - Sponsored by Charité Universitätsmedizin Berlin • New opportunities for an old problem: lowering potassium to maximize heart failure therapy - Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca • NT-proBNP: the gold standard biomarker in heart failure - Sponsored by Roche Diagnostics International Ltd. 	13:30 - 14:30	HUGO RENOIR MATISSE PIAF
<ul style="list-style-type: none"> • Guidelines in Daily Practice II: hospital discharge and outpatient management • Essentials of congestion in acute heart failure • Novel drugs in acute heart failure: hurdles, hype and hope • New solutions for old problems in heart failure • Insuffisance cardiaque systolique évolutive • Novel aspects of hereditary cardiomyopathies • Hot insights in metabolic interventions • Clinical Case Awards 	14:45 - 16:15	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Dilemmas in the dosing of HFrEF drugs • Acute right heart failure • Challenging clinical scenarios in acute heart failure • Controversies in cardiac resynchronisation therapy • Quand envisager une thérapeutique lourde? • Cancer and the heart • Attention needed for co-morbidities • The very best from clinical cases - I 	16:30 - 17:30	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Inaugural Session 	17:45 - 19:00	HUGO

SUNDAY 30 APRIL 2017

08:30 - 10:00	<ul style="list-style-type: none"> • Late Breaking Trials II 🌟 • Hot topics in diabetes and heart failure • What a busy clinician should know about heart failure with preserved ejection fraction? • Amyloidosis: don't miss it • Acute heart failure: immediate management • Novel drugs: how do they work? • Off the record with J. Cleland and M. Metra 🌟 • Nursing Investigator Award 🌟 	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
10:15 - 10:45	<ul style="list-style-type: none"> • The concept of timing in the therapeutic algorithm for chronic heart failure - Sponsored by SERVIER • Furosemide 2.0 - Subcutaneous administration of a novel formulation - Sponsored by scPharmaceuticals 	<p>AGORA 1 AGORA 2</p>
11:00 - 12:30	<ul style="list-style-type: none"> • Guidelines in Daily Practice III: pharmacological management based on LVEF 🌟 • Therapy of cardiogenic shock • Cardio-oncology: a partnership between heart failure specialists and oncologists • How to manage atrial fibrillation and low EF? 🌟 • Allez les Bleus! Groundbreaking French contributions to cardiology • Diabetes, obesity and the heart • Off the record with M. Crespo-Leiro 🌟 • Young Investigator Award: Clinical 🌟 	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
12:45 - 13:45	<ul style="list-style-type: none"> • A mitochondrial approach to heart failure - Sponsored by Charité Universitätsmedizin Berlin • Beat as one: a multidisciplinary approach to treating heart failure - Sponsored by St Jude Medical is now Abbott 	<p>RENOIR PIAF</p>
12:45 - 14:00	<ul style="list-style-type: none"> • Contemporary management of patients with heart failure with reduced Ejection Fraction (HFrEF) - Sponsored by Novartis • Management of co-morbidities in heart failure - Exploring new frontiers - Sponsored by Bayer AG • Implantable cardiac device therapy for heart failure: update 2017 - Sponsored by Medtronic • Iron deficiency in patients with heart failure: time for action - Sponsored by Vifor Pharma 	<p>HUGO MONET ZOLA MATISSE</p>
14:15 - 15:45	<ul style="list-style-type: none"> • How the results of recent randomized clinical trials will impact our practice • Management of comorbidities in chronic heart failure 🌟 • The year's best papers on heart failure 🌟 • New home-based strategies to improve physical exercise in heart failure patients • 50th anniversary of heart transplantation 🌟 • Young Investigator Award: Basic and Translational 🌟 	<p>HUGO MONET ZOLA RENOIR MATISSE AGORA 2</p>
15:55 - 16:25	<ul style="list-style-type: none"> • Optimising treatment of heart failure – Where are we today? - Sponsored by Novartis • Role of biomarkers to prevent heart failure development in diabetes patients - Sponsored by Roche Diagnostics International Ltd. 	<p>AGORA 1 AGORA 2</p>
16:00 - 16:30	<ul style="list-style-type: none"> • Award Ceremony 🌟 	<p>HFA STAND</p>
16:30 - 18:00	<ul style="list-style-type: none"> • The Grand Debate I: Nephilysin inhibitor - Vasodilators 🌟 🌟 🌟 • Heart failure patients with comorbidities • Practical recommendations for the clinician. How to treat... 🌟 • Emergencies in peripartum cardiomyopathy • Management of heart failure is an art: what to do when the guidelines provide no clear answer? • Sleep disordered breathing and heart failure - Time to rethink • Cardiorenal cross-roads 🌟 • Rapid Fire 3 - Acute heart failure - From diagnosis to prognosis 	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
18:15 - 19:15	<ul style="list-style-type: none"> • How innovative percutaneous Ventricular Assist Device (pVAD) systems improve outcomes in cardiogenic shock and facilitate complete revascularization in high risk Percutaneous Coronary Intervention (PCI) patients - Sponsored by Abiomed GmbH 	<p>PIAF</p>

MONDAY 1 MAY 2017

08:30 - 10:00	<ul style="list-style-type: none"> • Late Breaking Trials III  • Valvular disease in heart failure: vicious twins • Therapy of acute heart failure: how to use... • Heart failure management: when the clinician needs advice  • A practical guide: how to manage heart failure with mid-range ejection fraction (HFmrEF)? • Arrhythmias in heart failure - What are the mechanisms? • Ventricular assist systems: success and challenge • Rapid Fire 4 - Therapy and management 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
10:05 - 10:55	HFA General Assembly 	MATISSE
10:15 - 10:45	<ul style="list-style-type: none"> • Managing heart failure patients in day-to-day practice - Sponsored by SERVIER • Iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice - Sponsored by Vifor Pharma 	AGORA 1 AGORA 2
11:00 - 12:30	<ul style="list-style-type: none"> • Guidelines in Daily Practice IV: comorbidities: valvular and kidney disease  • How to use biomarkers in acute heart failure • How to tackle congestion • How to diagnose and treat myocarditis? • Novel aspects in heart transplantation • What to target outside of cardiac myocytes in heart failure • Multimodality imaging in heart failure: already today, not tomorrow!  • The very best from clinical cases - 2 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
12:45 - 13:45	<ul style="list-style-type: none"> • Heart failure, diabetes, and renal dysfunction: time for a more unified approach - Organised by Physicians Academy for Cardiovascular Education, supported by an unrestricted educational grant from Boehringer-Ingelheim and Lilly • Heart failure: what is the potential of SGLT2 inhibition? - Sponsored by AstraZeneca • Tricuspid regurgitation in heart failure: how to treat it? - Sponsored by Charité Universitätsmedizin Berlin • Understanding congestion: thinking beyond diuretic therapy - Sponsored by Fresenius Medical Care 	MONET ZOLA RENOIR PIAF
12:45 - 14:00	<ul style="list-style-type: none"> • The wearable cardioverter defibrillator: an essential tool in the management of patients at high risk for sudden cardiac death - Sponsored by ZOLL • Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels - Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma 	HUGO MATISSE
14:15 - 15:45	<ul style="list-style-type: none"> • HFA Championships   • How imaging can guide clinical decision making in heart failure • Cardiomyopathies: what the clinical cardiologist should know about...  • Comorbidities in heart failure: the bigger picture • Biomarkers in chronic heart failure • A fresh look on iron deficiency in heart failure • Off the record with M. Boehm  • Rapid Fire 5 - Diagnosis - Pathophysiology - Prognosis 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
15:55 - 16:25	<ul style="list-style-type: none"> • Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels - Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma • Heart failure, diabetes, and renal dysfunction: time for a more unified approach - Sponsored by PACE-CME - Boehringer-Ingelheim/Lilly 	AGORA 1 AGORA 2
16:30 - 18:00	<ul style="list-style-type: none"> • The Grand Debate 2: ICD – Myocardial revascularisation    • Valvular disease is myocardial disease • Biomarkers in my daily practice • Challenging heart team decisions in patients with ventricular assist systems • How should comorbidities in heart failure be treated? • Highlights of translational medicine • Rapid Fire 6 - Advanced heart failure 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 2

TUESDAY 2 MAY 2017

08:30 - 10:00

- Guidelines in Daily Practice V: arrhythmias and devices 🌐
- The right ventricle: the bright side of the moon
- Takotsubo: an acute heart failure syndrome
- Heart and brain interactions in heart failure: mechanisms and therapies
- Rapid Fire 7 - Acute heart failure

MONET
ZOLA
RENOIR
MATISSE
AGORA 2

11:00 - 12:30

- Heart Failure 2017 Highlights 🌐

MONET

